Pathology: la/mBC - HR positive; la/mBC - HR-positive - 1st line (L1); la/mBC - HR-positive - 2nd line (L2);
la/mBC - HR positive | la/mBC - HR-positive - 1st line (L1) | la/mBC - HR-positive - 2nd line (L2) | |||||
KCSG-BR15-10, 2019 | PENELOPE-B, 2021 | PALOMA-1, 2016 | PALOMA-2, 2016 | FLIPPER, 2021 | PALOMA-3, 2016 | ||
palbociclib plus endocrine therapy | 2 | T1 | T1 | ||||
palbociclib plus fulvestrant | 2 | T1 | T1 | ||||
palbociclib plus letrozole | 2 | T1 | T1 | ||||
endocrine therapy | 0 | T0 | |||||
capecitabine | 0 | T0 | |||||
fulvestrant | 0 | T0 | T0 | ||||
letrozole | 0 | T0 | T0 |